Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.68 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.68 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.67 |
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896309 | 1.00 | MEN1 (0.68) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3896302 | 1.00 | MEN1 (0.68) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3892654 | 0.92 | APEX1 (0.71) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3892650 | 0.92 | APEX1 (0.71) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3896590 | 0.92 | PTPN12 (0.67) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3896586 | 0.92 | PTPN12 (0.67) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3896603 | 0.90 | LCK (0.68) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3894518 | 0.90 | APEX1 (0.66) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL29466154 | 0.90 | APEX1 (0.66) | MEN1POLBKMT2AMAPTALDH1A1 | |
| SCHEMBL3894511 | 0.90 | APEX1 (0.66) | MEN1POLBKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250179172-A1 | CD5 ANTIBODY AND USE THEREOF | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4522628-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12187662-B2 | FOXM1 inhibitor compositions and methods of using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-01-07 | — | — | US | disclosed |
| CN-117210503-B | Recombinant adeno-associated virus vector for expressing nanobody and application thereof | 瑞诺元(苏州)生物科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117210503-A | Recombinant adeno-associated virus vector for expressing nanobody and application thereof | 瑞诺元(苏州)生物科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116731169-B | Nano antibody with sortilin 1 specificity and application thereof | 瑞诺元(苏州)生物科技有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116801905-A | CD5 antibody and application thereof | 先声再明医药有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116731169-A | Nano antibody with sortilin 1 specificity and application thereof | 瑞诺元(苏州)生物科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230097398-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-30 | — | — | US | disclosed |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| CN-114957357-A | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022127844-A1 | CD5 ANTIBODY AND USE THEREOF | 江苏先声药业有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-108350014-B | Aminoglycoside derivatives and their use in the treatment of genetic disorders | ELOXX制药有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11306115-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097398-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, IDUA, UGGT1 | MEN1 2403/4885POLB 1062/4885KMT2A 1782/4885 |
| US-11306115-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, IDUA, UGGT1 | MEN1 2403/4885POLB 1062/4885KMT2A 1782/4885 |
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | POLRMT, TARDBP, NSUN2 | MEN1 1631/4885POLB 20/4885KMT2A 1256/4885 |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | MEN1 1808/4885POLB 365/4885KMT2A 1554/4885 |
| US-12187662-B2 | FOXM1 inhibitor compositions and methods of using the same | FOXM1, FOXO1, TP53 | MEN1 2038/4885POLB 356/4885KMT2A 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.